Menstrual cramps affect up to 90 percent of people who menstruate, with as many as a third describing pain severe enough to disrupt work, school, and daily life. It is one of the most common pain conditions in medicine and one of the most routinely dismissed, normalized as something to push through rather than treated as the recurring, sometimes debilitating pain it is. That neglect is the backdrop for why so many people have reached for cannabis on their own, and why the research base, thin for years, has started to catch up to what patients have reported for a long time.
The reason cannabis is biologically plausible here is unusually concrete. Primary dysmenorrhea, the medical name for cramps without an underlying disease, is driven by prostaglandins: the uterine lining releases them, they force the uterine muscle into intense contractions, those contractions choke off blood flow, and the oxygen-starved tissue produces the metabolites that fire pain signals. Two things cannabinoids do map onto that chain directly. CBD inhibits the same prostaglandin-producing enzymes that ibuprofen inhibits, which is why a head-to-head trial of CBD against ibuprofen even makes sense as a study design. And the uterine muscle itself carries cannabinoid receptors (CB1, CB2, and TRPV channels have all been identified in human myometrial tissue), where cannabinoid agonists like THC trigger muscle relaxation. One cannabinoid works on the inflammatory signal, the other relaxes the cramping muscle.
This page treats menstrual cramps as a Pain cluster condition cross-referenced to women's health. It covers the mechanism, the evidence as it actually stands (strong observational data, characterized biology, controlled trials now underway), the protocol that fits a predictable cyclical pain, and the boundary that matters most: cramps that change or escalate can signal a secondary condition that needs its own diagnosis.
What the research actually shows about cannabis for menstrual cramps
The evidence sits in a recognizable shape for cannabis medicine: a well-characterized mechanism, a consistent observational signal, and controlled trials that are only now arriving. The most useful single reference is the Seifalian 2022 review in the International Journal of Molecular Sciences, which pulled together the biology and the clinical literature on cannabis for dysmenorrhea. It documented the endocannabinoid system's presence throughout the female reproductive tract and the role of cannabinoid receptors in myometrial contractility, and concluded that medicinal cannabis has promising applications for dysmenorrhea while calling for the higher-quality trials the field lacked. Walker 2019 in the Journal of Ovarian Research detailed the same underlying biology: endocannabinoid receptors, ligands, and enzymes distributed through the uterus and the wider reproductive system, with uterine expression modulated by estrogen across the cycle.
On the clinical side, the observational data is consistent. Carrubba 2021 documented cannabis use for self-management of chronic pelvic pain, and the broader Liang 2022 systematic review of medical cannabis for gynecologic pain conditions found that most cross-sectional studies reported pain relief, with the combination of CBD and THC outperforming either cannabinoid alone. The Sinclair 2023 review in Drugs placed cannabinoids within the gynecological pain treatment field and reached a compatible conclusion about the direction of the evidence.
The newer work is starting to move past surveys. A 2024 quasi-experimental study in npj Women's Health assessed a high-CBD vaginal suppository in a real-world population and found reduced menstrual symptom frequency, severity, and daily-life impact over two months, the first preliminary study of its kind for that delivery format. Controlled trials are now underway, including a non-inferiority trial comparing oral CBD directly against ibuprofen for primary dysmenorrhea, built around the shared prostaglandin mechanism. That trial design is telling in itself: researchers are confident enough in the mechanistic overlap between CBD and NSAIDs to test them as equivalents.
What the field does not yet have is a large, completed, placebo-controlled trial of an edible or oral cannabis product for cramps of the kind that now exists for chronic low back pain. The honest summary is that the mechanism is well understood, the observational evidence is consistent, the targeted suppository data is encouraging, and the randomized oral-cannabis evidence is in progress. That is a stronger position than most cannabis indications occupy, even without the definitive trial.
How the dual mechanism shapes the protocol
The two-mechanism picture is what makes a combined THC and CBD approach sensible for cramps rather than either cannabinoid alone. CBD addresses the prostaglandin-driven inflammatory signal at its source, the same target ibuprofen hits, which is the anti-inflammatory half of the job. THC acts on the cannabinoid receptors in the uterine muscle to relax the contractions that are producing the pain, the antispasmodic half. Using both covers both halves, which is consistent with the observational finding that CBD-plus-THC outperforms either one by itself.
The starting protocol is 5mg THC paired with 10mg CBD, and the timing is where cramps differ from most pain conditions. Because the cycle is predictable, the pain can be met early or even pre-empted rather than chased. Taking the dose at the first twinge of cramping, or the evening before an expected period, gives the cannabinoids time to act before the contractions peak. This is the same proactive logic that works for endometriosis pain, and it is more effective than waiting until a bad cramp has already taken hold. Repeat through the worst one or two days, keeping the total modest; most people who respond do so without needing large doses.
Format matters for the acute cramp. A traditional gummy taking 60 to 90 minutes to work is slow against a cramp that builds over minutes, so a faster-onset format (a nano-emulsion gummy, a beverage, or a sublingual product) suits the acute episode better. For someone who wants steady coverage across a heavy-cramping day, a longer-acting traditional edible taken proactively in the morning can hold a baseline, with a faster format layered on for breakthrough. The predictability of the cycle makes this planning straightforward in a way that unpredictable pain conditions do not allow.
The suppository question comes up often enough to address directly. Vaginal and rectal cannabinoid suppositories deliver the compounds close to the pelvic tissue, and much of the most targeted research (including the npj suppository study) has used that route. Edibles work systemically, reaching the uterine tissue through the bloodstream. For most people an edible is more accessible and engages the same two mechanisms, with the honest caveat that some of the most direct evidence used localized delivery. Neither format has clearly beaten the other in head-to-head data, so the choice comes down to accessibility and preference more than a proven efficacy gap.
Primary versus secondary cramps, and where cannabis fits
The distinction that matters clinically is between primary and secondary dysmenorrhea. Primary dysmenorrhea is cramping without an underlying pelvic disease, driven by the prostaglandin mechanism, and it typically starts within a year or two of the first period and follows a stable pattern through the reproductive years. This is the population the dual-mechanism cannabinoid approach fits best, because the target is the prostaglandin-and-contraction chain itself.
Secondary dysmenorrhea is cramping caused by an underlying condition, most commonly endometriosis, but also adenomyosis and uterine fibroids. The tell is a change in pattern: cramps that begin later in life, escalate over time, extend beyond the menstrual days, or arrive with pain during intercourse or abnormal bleeding. Cannabis may still help the pain of secondary dysmenorrhea, and the endometriosis pain page covers that mixed-mechanism picture in depth, but the underlying condition needs its own diagnosis and treatment. Using cannabis to manage the pain of an undiagnosed secondary cause risks masking a condition that has real consequences for fertility and long-term health.
Within the pharmacological options for primary dysmenorrhea, cannabis positions itself alongside NSAIDs rather than replacing the first-line role NSAIDs hold. Ibuprofen and similar drugs work well for many people and remain the standard starting point. Cannabis becomes most useful for the substantial minority (roughly a fifth to a quarter of patients) whose cramps do not respond adequately to NSAIDs, or who cannot tolerate them because of gastrointestinal side effects. For that group, a cannabinoid approach that hits the same prostaglandin target through a different route, and adds direct muscle relaxation on top, is a reasonable next step rather than a fringe one. The standard interaction caution applies: CBD can affect the metabolism of other medications at higher doses than this protocol uses, and anyone combining cannabis with prescription treatment should keep the prescriber informed.